# OnCo record menopause-after-cancer-treatment (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/menopause-after-cancer-treatment/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "menopause-after-cancer-treatment" ;
  schema:name "Menopause brought on by cancer treatment, and the options for it"@en ;
  schema:description "Treatment can bring on menopause in a week rather than a decade, and the usual answer, hormone replacement, is often unavailable. The non-hormonal options now have real trial evidence: elinzanetant cut moderate to severe hot flushes by three and a half episodes a day more than placebo in women on endocrine therapy, and venlafaxine and oxybutynin also beat placebo."@en ;
  schema:url <https://onco.cc/technologies/menopause-after-cancer-treatment/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Menopause> ;
  schema:citation <https://doi.org/10.1056/NEJMoa2415566>, <https://doi.org/10.1016/S0140-6736(00)03403-6>, <https://doi.org/10.1093/jncics/pkz088>, <https://doi.org/10.1136/bmj.c693>, <https://doi.org/10.1200/JCO.2017.75.8995> ;
  onco:status "established" ;
  onco:tag "rejuvenation", "survivorship", "evidence:strong" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/cervical/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/hormonal/> ;
  onco:technologies <https://onco.cc/technologies/ovarian-function-after-chemotherapy/>, <https://onco.cc/technologies/vaginal-oestrogen-after-breast-cancer/>, <https://onco.cc/technologies/sexual-function-after-cancer/>, <https://onco.cc/technologies/cancer-treatment-bone-loss/>, <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/mindfulness-based-interventions/> ;
  onco:drugs <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/anastrozole/>, <https://onco.cc/drugs/exemestane/>, <https://onco.cc/drugs/goserelin/> ;
  onco:terms <https://onco.cc/terms/menopause-after-chemotherapy-breast/>, <https://onco.cc/terms/ovarian-function-suppression/>, <https://onco.cc/terms/aromatase-inhibitor/>, <https://onco.cc/terms/late-effects/> ;
  onco:trials <https://onco.cc/trials/nct05587296/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct05587296-n-engl-j-med-2025/> .